Federal grants to Creative Bio-Peptides, Inc.
Creative Bio-Peptides, Inc. in Potomac, Maryland received $8.8 million in federal grants from fiscal 2021 to 2025, across 5 awards. Its largest program was Drug Use and Addiction Research Programs, with $5.3 million. In fiscal 2025 it was awarded $1.1 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$8.8 million
- Awards5
- Awarded in FY 2025$1.1 million
- Largest award$3.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 3 | $4.7 million |
| FY 2022 | 1 | $1.1 million |
| FY 2023 | 1 | $324,790 |
| FY 2024 | 2 | $1.6 million |
| FY 2025 | 1 | $1.1 million |
Programs that fund Creative Bio-Peptides, Inc.
| Program | Awards | Amount |
|---|---|---|
| Drug Use and Addiction Research Programs | 2 | $5.3 million |
| Aging Research | 3 | $3.5 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 5 | $8.8 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Development of a novel chemokine receptor antagonist peptide as a non-opioid treatment for relief of chronic pain - 7. Project summary in response to RFS-NS-20-11, creative bio-peptides, inc. Will develop the multi-chemokine receptor antagonist peptide R103 to provide a non-opioid, potentially disea | Drug Use and Addiction Research Programs | September 9, 2021 | $3.0 million |
| A synapse-protecting small peptide to treat a-syn/tau mixed proteinopathies in alzheimer's disease related dementias (ADRD) - 7. Project summary there is strong evidence of co-morbid pathologies (Α-synuclein, amyloid Β, tau) in age-related dementias that cause synergistic contributions to neurodegen | Aging Research | July 31, 2024 | $2.5 million |
| Development of a novel chemokine receptor antagonist as a treatment for opioid use disorder - 7. Project summary over 2.1 million americans suffer from opioid use disorder (OUD) resulting in 47,000 deaths annually. Individuals seeking treatment must deal with limited access to qualified healthcare p | Drug Use and Addiction Research Programs | September 22, 2021 | $2.3 million |
| Pet imaging to evaluate a novel chemokine antagonist to protect synapses in adrd - 7. Project summary adrd dementias account for up to 25% of all dementias in patients older than 65 years and there is strong evidence of co-morbid pathologies caused by (amyloid ss (ASS), tau and a-synuclein (ASYN). T | Aging Research | September 25, 2023 | $499,906 |
| Optimization of a chemokine receptor antagonist peptide as a synapse protecting treatment for neurodegeneration in alzheimer's disease - 7. Project summary ad in response to PAS-19-319, creative bio-peptides, inc. Proposes a novel therapeutic approach to protect and restore synapses in alzheimer’s d | Aging Research | September 6, 2021 | $499,860 |
Questions people ask
How much federal grant money does Creative Bio-Peptides, Inc. get?
$8.8 million in 5 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Creative Bio-Peptides, Inc. the most?
The Department of Health and Human Services, with $8.8 million in 5 awards.
What is Creative Bio-Peptides, Inc.'s largest federal grant?
$3.0 million under Drug Use and Addiction Research Programs, with its first action in the period on September 9, 2021. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Creative Bio-Peptides, Inc.?
Its largest are Drug Use and Addiction Research Programs and Aging Research.
Other grant recipients in Potomac
Largest federal grant recipients in Maryland · Federal grants in Maryland